Trial Profile
Impact of Apixaban on clinical outcome of the patients with Large Vessel Occlusion or stenosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Acronyms ALVO trial
- 21 Feb 2020 Results estimating the cumulative incidences of bleeding and ischemic events as well as all-cause mortality in patients on apixaban for nonvalvular atrial fibrillation and and acute large vessel occlusion, presented at the International Stroke Conference 2020
- 03 Aug 2019 Status changed from recruiting to completed.
- 22 Jun 2016 New trial record